The therapeutic outcomes and adverse drug reactions study of Clozapine on Schizophrenia inpatients in the Grhasia psychiatric hospital Yogyakarta, Indonesia

被引:0
作者
Harjaningsih, Woro [1 ]
Ayunirrahmah, Laila [2 ]
Putri, Nur Jannah Virsya [2 ]
机构
[1] Univ Gadjah Mada, Fac Pharm, Div Pharmacol & Clin Pharm, Yogyakarta, Indonesia
[2] Univ Gadjah Mada, Fac Pharm, Yogyakarta, Indonesia
来源
PHARMACY EDUCATION | 2021年 / 21卷 / 02期
关键词
Adverse drug reaction; Clozapine; Schizophrenia; Therapeutic outcome; INDUCED WEIGHT-GAIN; HTR2C GENE;
D O I
10.46542/pe.2021.212.287295
中图分类号
G40 [教育学];
学科分类号
040101 ; 120403 ;
摘要
Introduction: Clozapine is an antipsychotic agent used in schizophrenia recurrence or when other antipsychotics are not effective. Aims: This study aims to determine the therapeutic outcome and adverse drug reactions of clozapine in schizophrenia disorder among hospitalised patients. Methods: A retrospective cross-sectional study was conducted between January 2018 and December 2019 using inpatients' medical records from the Grhasia Psychiatric Hospital, Yogyakarta. The therapeutic outcome was measured with the PANSS-EC scale, while adverse drug reactions of clozapine were analysed theoretically as per the literature. Results: The average decrease in the PANSS-EC score was 8.27, and the average duration to achieve this decrease was 2.5 days. The combination of typical-atypical antipsychotics could reduce the highest PANSS-EC score of 11-15 (41%). The adverse drug reactions of clozapine were tremor, weight gain, obesity, leucopenia, hyperglycemia, and hypercholesterolemia, among other effects. Conclusion: Clozapine is effective in improving positive and negative symptoms, but its use needs close monitoring.
引用
收藏
页码:287 / 295
页数:9
相关论文
共 35 条
[1]  
Alldredge B.K., 2013, GERONTOLOGY C EC P, V10th
[2]  
Andreasen N.C., 2006, INTRO TXB PSYCHIAT, V4th
[3]  
[Anonymous], 2017, Pharmacotherapy: A Pathophysiologic Approach, 10e
[4]  
AphA, 2019, DRUG INFORM HDB, V21th
[5]  
Aryani F., 2016, J MANAGEMENT PHARM P, V6, P35, DOI [10.22146/jmpf.236, DOI 10.22146/JMPF.236]
[6]   The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements [J].
Buchanan, Robert W. ;
Kreyenbuhl, Julie ;
Kelly, Deanna L. ;
Noel, Jason M. ;
Boggs, Douglas L. ;
Fischer, Bernard A. ;
Himelhoch, Seth ;
Fang, Beverly ;
Peterson, Eunice ;
Aquino, Patrick R. ;
Keller, William .
SCHIZOPHRENIA BULLETIN, 2010, 36 (01) :71-93
[7]  
Crismon M.L., 2015, SCHIZOPHRENIA PHARMA, V9th
[8]   Antipsychotic-associated weight gain: management strategies and impact on treatment adherence [J].
Dayabandara, Madhubhashinee ;
Hanwella, Raveen ;
Ratnatunga, Suhashini ;
Seneviratne, Sudarshi ;
Suraweera, Chathurie ;
de Silva, Varuni A. .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2017, 13 :2231-2241
[9]   Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine [J].
De Berardis, Domenico ;
Rapini, Gabriella ;
Olivieri, Luigi ;
Di Nicola, Domenico ;
Tomasetti, Carmine ;
Valchera, Alessandro ;
Fornaro, Michele ;
Di Fabio, Fabio ;
Perna, Giampaolo ;
Di Nicola, Marco ;
Serafini, Gianluca ;
Carano, Alessandro ;
Pompili, Maurizio ;
Vellante, Federica ;
Orsolini, Laura ;
Martinotti, Giovanni ;
Di Giannantonio, Massimo .
THERAPEUTIC ADVANCES IN DRUG SAFETY, 2018, 9 (05) :237-256
[10]   Association of the HTR2C gene and antipsychotic induced weight gain:: a meta-analysis [J].
De Luca, Vincenzo ;
Mueller, Daniel J. ;
de Bartolomeis, Andrea ;
Kennedy, James L. .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2007, 10 (05) :697-704